Evidence mapPaperPMID 39081955Full record

ReviewFrontiers in pharmacology2024

Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine.

Shihao Zheng, Chengyuan Xue, Size Li, Xiaobin Zao, Xiaoke Li, Qiyao Liu, Xu Cao, Wei Wang, Wenying Qi, Hongbo Du and 2 more

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Exploring Cirrhosis: Insights into Advances in Therapeutic Strategies.International journal of molecular sciences · 2025
    Review
  6. Article
  7. [Research progress on liver fibrosis, cirrhosis, and portal hypertension in 2024].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shihao ZhengDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Chengyuan XueDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Size LiDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Xiaobin ZaoDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Xiaoke LiDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Qiyao LiuDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Xu CaoDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Wei WangDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Wenying QiDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Hongbo DuDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Peng ZhangDongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Yongan YeDongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cirrhosis arises from liver fibrosis and necroinflammation caused by various mechanisms of hepatic injury. It is a prevalent condition in clinical practice characterized by hepatocellular dysfunction, portal hypertension, and associated complications. Despite its common occurrence, the etiology and pathogenesis of liver cirrhosis remain incompletely understood, posing a significant health threat. Effective prevention of its onset and progression is paramount in medical research. Symptoms often include discomfort in the liver area, while complications such as sarcopenia, hepatic encephalopathy, ascites, upper gastrointestinal bleeding, and infection can arise. While the efficacy of Western medicine in treating liver cirrhosis is uncertain, Chinese medicine offers distinct advantages. This review explores advancements in liver cirrhosis treatment encompassing non-pharmacological and pharmacological modalities. Chinese medicine interventions, including Chinese medicine decoctions, Chinese patent medicines, and acupuncture, exhibit notable efficacy in cirrhosis reversal and offer improved prognoses. Nowadays, the combination of Chinese and Western medicine in the treatment of liver cirrhosis also has considerable advantages, which is worthy of further research and clinical promotion. Standardized treatment protocols based on these findings hold significant clinical implications.

Indexed as

Chinese medicinecurrent statusliver cirrhosispharmacologytreatment options

Identifiers

PMID39081955
PMCPMC11286405

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.